Search Resources (English): Drug industry, Women and Health Protection (WHP)

Results 1 - 10 of 11

Results

A different prescription: considerations for women's health groups contemplating funding from the pharmaceutical industry  
http://www.whp-apsf.ca/en/documents/diff_prescrip.html

Discusses diverse perspectives on the issue of women's health groups accepting money from the pharmaceutical industry.

 (See Details)
Published: 1999
The marketization of depression: the prescribing of SSRI antidepressants to women  
http://www.whp-apsf.ca/pdf/SSRIs.pdf

Looks at the impact of SSRI use among Canadian women. Reviews what is currently known about the benefits and harms caused by SSRIs, as well as both the definition and incidence of depression in women.

 (See Details)
Published: 2005
Who benefits: international harmonisation of the regulation of new pharmaceutical drugs  
http://www.whp-apsf.ca/en/documents/who_benefits.html
Explains how the push to streamline the drug approval process in the world's three largest pharmaceutical markets is neglecting the special needs of women. (See Details)
Published: 2002
Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross secti  
http://bmj.bmjjournals.com/cgi/content/full/324/7332/278
Examines the relation between direct to consumer advertising and patients' requests for prescriptions and the relation between patients' requests and prescribing decisions. (See Details)
Published: 2002
The marketing of fear  
http://www.whp-apsf.ca/en/documents/afr_mrktng.html
Examines the tactics of pharmaceutical companies, especially direct-to-consumer advertising. (See Details)
Published: 2000
Women's cycles up for sale: neo-medicalization and women's reproductive health  
http://www.cwhn.ca/node/39520
Examines the medicalization of women's reproductive functions, including treating normal health cycles as problems or illnesses. (See Details)
Published: 2004
Marching to different drummers: health advocacy groups in Canada and funding from the pharmaceutical industry  
http://www.whp-apsf.ca/pdf/corpFunding.pdf
Explores drug company funding of health and disease advocacy groups. Argues that it creates a conflict of interest that needs to be recognized and addressed. (See Details)
Published: 2005
Drug company funding dominates non-profit organizations, report finds  
http://www.cwhn.ca/node/39464
Provides highlights of a Women and Health Protection report that describes the ways in which drug companies provide funding for health advocacy groups. (See Details)
Published: 2006
Remembering Ruth Cooperstock: women and pharmaceuticals 20 years later  
http://www.whp-apsf.ca/pdf/coopProceedingsEN.pdf
Presents the proceedings of a symposium that examined women and the pharmaceuticals industry. Includes presentations of the three panellists and a brief summary of each of the workshops. (See Details)
Published: 2006
How safe are our medicines? Monitoring the risks of drugs after they are approved for marketing  
http://www.whp-apsf.ca/en/documents/how_safe.html
Discusses the drug approval process in Canada, post-approval drug surveillance, adverse drug reactions, and notification of those at risk of harm. Recommends measures to ensure drug safety for Canadian women and their families. (See Details)
Published: 2000